Skip to main content

Table 1 Patient baseline characteristics (n = 780)

From: Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants

 

Group A

Bridging

n = 111

Group B

VKA

n = 318

Group C

DOAC

n = 351a

p-value

A-B

p-value

A-C

p-value

B-C

Age (years)

59.1 ± 9.8

59.6 ± 10.2

59.5 ± 10.0

0.706

0.809

0.841

Female gender

32 (29)

98 (30)

115 (32.8)

0.721

0.484

0.618

BMI (kg/m2)

28.0 ± 4.07

27.9 ± 4.6

28 ± 10

0.629

0.919

0.822

Ejection fraction (%)

63 ± 11.4

62 ± 8

63 ± 5

0.797

0.276

0.077

Atrial fibrillation

   

0.316

0.092

< 0.001

 Paroxysmal AF

57 (51.4)

137 (43.1)

221 (63.0)

   

 Persistent AF

43 (38.7)

142 (44.7)

102 (29.1)

   

 Atypical AF

28 (8.0)

39 (12.3)

28 (8.0)

   

LA Diameter (mm)

44.2 ± 5.5

43.3 ± 4.7

41.5 ± 4.3

0.093

< 0.001

< 0.001

Comorbidity

 Hypertension

90 (80.1)

237 (74.5)

228 (65)

0.195

0.001

0.009

 CAD

23 (20.7)

53 (16.7)

41 (11.7)

0.386

0.026

0.075

 Diabetes

7 (6.3)

28 (8.8)

24 (6.8)

0.546

1.0

0.387

 Stroke/TIA

7 (6.3)

19 (6.0)

54 (5.7)

1.0

0.813

0.867

  1. Legend: aDabigatran (n = 170), Rivaroxaban (n = 112), Apixaban (n = 69); AF atrial fibrillation, BMI body-mass-index, EF ejection fraction, CAD coronary artery disease, Bridging interrupted vitamin-K-antagonist bridged with heparin, DOAC uninterrupted non-vitamin-K anticoagulants, TIA transient ischemic attack, VKA uninterrupted vitamin-K-antagonist